Getting the right drug to the right patient at the right place at the right time
Our focus on the future of patient outcomes informs nearly all we do — from scaling and customizing our end-to-end services for your specific needs to developing technology that connects stakeholders with critical information throughout the process.
And we'll continue to use data and partner feedback to keep pace with your ambitions for years to come. Together, we can make a difference in patients' lives and accelerate healthier futures.
We sat down with Lung-I Cheng, Vice President, Cell and Gene Therapy, to get his perspectives on this emerging category.
Q: What did you see about AmerisourceBergen that made you want to work here?
Lung-I Cheng: I look at the healthcare system as a holistic ecosystem. I'm new to distribution, having come from a biopharma background. Yet, if we think about what we're trying to achieve, getting medicines to patients who need them, I see myself as one of the partners.
Q: What are the top trends in the cell and gene space? How do you envision AmerisourceBergen leveraging those trends to help our partners?Lung-I Cheng: The science keeps evolving fast, and cell therapy is no longer a proof of concept. These approved cell therapies have brought tremendous benefits to patients but in relatively small populations. However, there is a multitude of targets and disease areas that are being studied. And I think the number of approvals and positive impact on patients will pick up soon. With the promise of approvals, it will take a group effort to ensure that patient access remains top of mind. And ultimately, that's what we do as AmerisourceBergen: answer "How do you get the drug to the patient?"
Another exciting aspect of cell and gene therapy is that we see significant R&D investments globally, unlike other modalities that came before it. Right now, China has the second-highest number of clinical trials in cell and gene therapy. How we translate this momentum in R&D into patient access and commercial successes worldwide will be a focus area for many stakeholders involved. AmerisourceBergen is well-positioned because we have a global reach in many markets outside the U.S., especially through our ICS and World Courier businesses.
A third trend is the speed of platform improvements. For example, with autologous cell therapies, there's a lot of effort trying to reduce vein-to-vein time, the interval between when patients' immune cells are extracted to when the engineered cells are injected back into them. Because many of these patients have aggressive diseases, reducing this vein-to-vein time is critical. Some companies have started exploring expanding these engineered cells in vivo (in the patient). We must approach accessibility from different angles as the platforms continue improving.
Q: What should a biopharma company be looking for in a cell and gene commercialization partner?Lung-I Cheng: Patients are at the center of everything. To that end, it is natural to ask: is this a partner that can, a hundred percent of the time, get the right drug to the right patient in the right place at the right time? AmerisourceBergen has our history, our expertise, and the right tools in place to make that happen. Furthermore, we want to innovate with biopharma partners because there will be new challenges as the field evolves. We are committed to co-creating innovative solutions to meet those challenges.
Q: What are some market access and reimbursement opportunities and challenges in the cell and gene space?Lung-I Cheng: Regarding reimbursement, we need to consider coverage, coding, and payment levels. In the United States, achieving coverage with cell and gene therapies has gone reasonably well. What was challenging, at least in the first few years, was the lack of a specific diagnosis-related group (DRG) code for autologous cell therapies, which then created uncertainty for providers as to whether they would be reimbursed appropriately for the services provided. The Centers for Medicare & Medicaid Services have since issued a decided DRG code for those therapies.
In Europe, by contrast, the reimbursement hurdle is more about getting the coverage than the payments; however, in some countries, insufficient payment could still be an issue. The first few cell therapies in lymphoma are deemed to have "curative potential," which helped with the reimbursement negotiations in European markets. However, we are now seeing headwinds with several recently launched cell and gene therapies where the product value is not aligned with what the European payers have in mind.
The issue is even more complex for emerging markets, ranging from logistics and affordability. Some national payers have explored innovative contracting solutions to pay for cell and gene therapies with mixed success.
Q: From an equitable access perspective, a lot still needs doing to bring these innovative treatments to more patients. How can the right commercialization partner help with commercialization challenges?Lung-I Cheng: The challenge for biopharma companies with cell and gene therapy reimbursement is you must start planning much earlier. For instance, an appropriate or inappropriate endpoint in the pivotal clinical trial could influence whether an outcomes-based contract could be implemented at commercial launch. Biopharma companies must pull commercial functions into those early R&D discussions, as the decisions have downstream implications.
What sometimes gets overlooked is also that for cell and gene therapy, unlike other modalities, the clinical trial sites will most likely become commercial sites. How a treatment is distributed for the clinical trial and how the sites of care interface with the biopharma companies to impact the commercial launch.